Skip to main content

25-08-2023 | Heart Failure | Editor's Choice | News

Semaglutide beneficial for patients with HFpEF and obesity

Author: Dr. Shreeya Nanda

medwireNews: Results from the STEP-HFpEF trial suggest that patients with heart failure with preserved ejection fraction (HFpEF) and obesity could benefit from treatment with semaglutide 2.4 mg/week.

Related topics